{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T09:28:39Z","timestamp":1779010119405,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ijantimicag.2016.07.009","type":"journal-article","created":{"date-parts":[[2016,8,21]],"date-time":"2016-08-21T02:09:08Z","timestamp":1471745348000},"page":"551-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides"],"prefix":"10.1016","volume":"48","author":[{"given":"Antonio","family":"Di Biagio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"Capetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Cenderello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Vittorio","family":"de Socio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Cassola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Quirino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Viscoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096187","article-title":"Simplification to abacavir\/lamivudine\u2009+\u2009atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial","volume":"9","author":"Wohl","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0015","first-page":"99","article-title":"Role of atazanavir in the treatment of HIV infection","volume":"5","author":"Rivas","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"4 Suppl. 3","key":"10.1016\/j.ijantimicag.2016.07.009_bib0020","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.7448\/IAS.17.4.19810","article-title":"Long term effectiveness of once-daily unboosted atazanavir plus abacavir\/lamivudine as a switch strategy in subjects with virological suppression","volume":"17","author":"Llibre","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0025","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/jac\/dkr316","article-title":"Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy","volume":"66","author":"Pavie","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/hiv.12118","article-title":"A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction","volume":"15","author":"Baril","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/QAI.0000000000000849","article-title":"Discontinuation of initial antiretroviral therapy in clinical practice: moving toward individualized therapy","volume":"71","author":"Di Biagio","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0040","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkv083","article-title":"Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database","volume":"70","author":"Raffi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0045","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0050","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","article-title":"Simplification to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants","volume":"28","author":"Palella","year":"2014","journal-title":"AIDS"},{"issue":"4 Suppl. 3","key":"10.1016\/j.ijantimicag.2016.07.009_bib0060","doi-asserted-by":"crossref","first-page":"19796","DOI":"10.7448\/IAS.17.4.19796","article-title":"Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study","volume":"17","author":"Gazaignes","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0065","first-page":"299","article-title":"Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014","volume":"38","author":"Antinori","year":"2015","journal-title":"New Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/hiv.12157","article-title":"Successful switch to rilpivirine\/tenofovir\/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy","volume":"15","author":"Rokx","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0085","first-page":"1","article-title":"Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia","volume":"7","author":"Thamrongwonglert","year":"2016","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/499056","article-title":"Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C\u2192T polymorphism at the multidrug resistance gene 1","volume":"42","author":"Rodr\u00edguez N\u00f3voa","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0095","first-page":"144","article-title":"Novel antiretroviral drugs and renal function monitoring of HIV patients","volume":"16","author":"Maggi","year":"2014","journal-title":"AIDS Rev"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12879-015-1077-7","article-title":"New highly active antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy)","volume":"15","author":"Restelli","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.07.009_bib0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/CEOR.S69183","article-title":"Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort","volume":"7","author":"Tontodonati","year":"2014","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916302059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916302059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:08:56Z","timestamp":1718755736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916302059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0924857916302059"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.07.009","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}